MedTrace Logo

To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects

NCT02462031 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2015-06-03

No results posted yet for this study

Summary

To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.

Conditions

Interventions

DRUG

KD101

200mg, 400mg, 800mg, 1400mg

DRUG

placebo

200mg, 400mg, 800mg

Sponsors & Collaborators

  • Kwang Dong Pharmaceutical co., ltd.

    lead INDUSTRY

Principal Investigators

  • Howard Lee, Professor · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462031 on ClinicalTrials.gov